PDF(Pubmed)
Abstract：
Over the past quarter century, product development partnerships (PDPs) have importantly brought health technologies, particularly for neglected diseases, to market for low- and middle-income countries (LMICs). With public sector financing, PDPs de-risk the gulf between where the global burden of disease falls and where paying markets exist. From fighting COVID-19 to developing novel antibiotics, the work of PDPs now extends beyond these traditional bounds. As PDPs have shepherded more health technologies to market, they are also confronting new access challenges. This article lays out 5 areas to strategically leverage the PDP model for better access to new health technologies. Making the case for enhanced support of the PDP approach will require greater transparency, as well as recognition of the contributions made by both public and private sector partners. The governance and funding of PDPs must be accountable to meeting the needs and building capacity of target beneficiaries in LMICs. To take an end-to-end approach, PDPs must work in tandem with other public sector institutions as well as local manufacturers as part of a larger innovation ecosystem. PDPs will need to keep pace with both the dynamics of diseases and markets in delivering the next generation of much needed health technologies.
Product development partnerships (PDPs) play an important role in bringing new and needed health technologies to market, particularly in low- and middle-income countries. As these products emerge from the R&D pipeline, new access challenges in paying for and delivering them in the health care system have emerged. The COVID-19 pandemic has also both stretched and tapped into this work. These developments provide a window of opportunity, both to take stock of lessons learned and of strategic opportunities to leverage the PDP model beyond its traditional bounds of neglected diseases. Greater transparency and recognition of the contributions of PDPs, accountability of governance and surety of financing, and coordination with pooled procurement and local manufacturing initiatives can build a foundation for even more impactful contributions in the future.
Product development partnerships (PDPs) play an important role in bringing new and needed health technologies to market, particularly in low- and middle-income countries. As these products emerge from the R&D pipeline, new access challenges in paying for and delivering them in the health care system have emerged. The COVID-19 pandemic has also both stretched and tapped into this work. These developments provide a window of opportunity, both to take stock of lessons learned and of strategic opportunities to leverage the PDP model beyond its traditional bounds of neglected diseases. Greater transparency and recognition of the contributions of PDPs, accountability of governance and surety of financing, and coordination with pooled procurement and local manufacturing initiatives can build a foundation for even more impactful contributions in the future.
摘要：
在过去的四分之一世纪里，产品开发伙伴关系(PDP)带来了重要的健康技术，特别是对于被忽视的疾病，面向低收入和中等收入国家(LMICs)的市场。在公共部门的资助下，PDP降低了全球疾病负担下降与存在付费市场之间的鸿沟。从对抗COVID-19到开发新型抗生素，PDPs的工作现在超出了这些传统的界限。随着PDP将更多的健康技术推向市场，他们也面临新的准入挑战。本文列出了5个方面，以战略性地利用PDP模型来更好地获取新的健康技术。加强对PDP方法的支持将需要更大的透明度，以及对公共和私营部门伙伴的贡献的认可。PDP的治理和供资必须对满足LMICs目标受益者的需求和能力建设负责。要采取端到端的方法，作为更大的创新生态系统的一部分，PDP必须与其他公共部门机构以及当地制造商协同工作。PDP将需要跟上疾病和市场的动态，以提供下一代急需的卫生技术。
产品开发合作伙伴关系（PDP）在将新的和所需的健康技术推向市场方面发挥着重要作用。特别是在低收入和中等收入国家。随着这些产品从研发管道中脱颖而出，在医疗保健系统中支付和提供这些服务方面的新挑战已经出现。COVID-19大流行也延伸并利用了这项工作。这些发展提供了机会之窗,总结经验教训和战略机遇，利用PDP模式超越其传统的被忽视疾病的界限。更大的透明度和对PDP贡献的认可，治理问责和融资担保，与集合采购和本地制造计划的协调可以为将来更有影响力的贡献奠定基础。
产品开发合作伙伴关系（PDP）在将新的和所需的健康技术推向市场方面发挥着重要作用。特别是在低收入和中等收入国家。随着这些产品从研发管道中脱颖而出，在医疗保健系统中支付和提供这些服务方面的新挑战已经出现。COVID-19大流行也延伸并利用了这项工作。这些发展提供了机会之窗,总结经验教训和战略机遇，利用PDP模式超越其传统的被忽视疾病的界限。更大的透明度和对PDP贡献的认可，治理问责和融资担保，与集合采购和本地制造计划的协调可以为将来更有影响力的贡献奠定基础。
